retatrutide triple hormone receptor agonist obesity Original Article: Triple–Hormone-Receptor for — A Phase 2 Trial https://t.co/jNL1GNnHPT #ADA23 retatrutide triple agonist glp-1 gip

EC 4.1.2

PMCID: PMC4048923

Interestingly, appendicular BMD, but not axial BMD, was not reduced despite significant weight loss in the semaglutide group and no changes in BTMs or bone microarchitecture was encountered [70]

"However, robust scientific evidence is still lacking, necessitating caution and a wait for more substantial data." Even if GLP-1 RAs prove to have therapeutic benefit for fertility, considerations such as availability and cost may affect prescribing

Springer London, pp 8392 Cabas-Mora G, Daza A, Soto-Garca N et al (2024) Peptipedia v2.0: a peptide sequence database and user-friendly web platform

Please call for current program details